137 related articles for article (PubMed ID: 36583936)
21. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
[TBL] [Abstract][Full Text] [Related]
22. Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).
Schmidt ST; Pedersen GK; Neustrup MA; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Front Immunol; 2018; 9():898. PubMed ID: 29760705
[TBL] [Abstract][Full Text] [Related]
23. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.
Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM
Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346
[TBL] [Abstract][Full Text] [Related]
24. Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System.
Ciabattini A; Pettini E; Fiorino F; Lucchesi S; Pastore G; Brunetti J; Santoro F; Andersen P; Bracci L; Pozzi G; Medaglini D
Front Immunol; 2018; 9():380. PubMed ID: 29593710
[TBL] [Abstract][Full Text] [Related]
25. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.
Yu H; Karunakaran KP; Jiang X; Shen C; Andersen P; Brunham RC
Infect Immun; 2012 Apr; 80(4):1510-8. PubMed ID: 22290151
[TBL] [Abstract][Full Text] [Related]
26. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
Agger EM; Rosenkrands I; Hansen J; Brahimi K; Vandahl BS; Aagaard C; Werninghaus K; Kirschning C; Lang R; Christensen D; Theisen M; Follmann F; Andersen P
PLoS One; 2008 Sep; 3(9):e3116. PubMed ID: 18776936
[TBL] [Abstract][Full Text] [Related]
27. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
[TBL] [Abstract][Full Text] [Related]
28. Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection.
Woodworth JS; Christensen D; Cassidy JP; Agger EM; Mortensen R; Andersen P
Mucosal Immunol; 2019 May; 12(3):816-826. PubMed ID: 30760832
[TBL] [Abstract][Full Text] [Related]
29. Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation.
Prota G; Christensen D; Andersen P; Medaglini D; Ciabattini A
Vaccine; 2015 Nov; 33(48):6823-30. PubMed ID: 26494626
[TBL] [Abstract][Full Text] [Related]
30. Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to
Riccomi A; Piccaro G; Christensen D; Palma C; Andersen P; Vendetti S
Front Immunol; 2019; 10():934. PubMed ID: 31130946
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.
Vangala A; Kirby D; Rosenkrands I; Agger EM; Andersen P; Perrie Y
J Pharm Pharmacol; 2006 Jun; 58(6):787-99. PubMed ID: 16734980
[TBL] [Abstract][Full Text] [Related]
32. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
[TBL] [Abstract][Full Text] [Related]
33. Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.
Vono M; Eberhardt CS; Mohr E; Auderset F; Christensen D; Schmolke M; Coler R; Meinke A; Andersen P; Lambert PH; Mastelic-Gavillet B; Siegrist CA
Front Immunol; 2018; 9():381. PubMed ID: 29541075
[TBL] [Abstract][Full Text] [Related]
34. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice.
Gram GJ; Karlsson I; Agger EM; Andersen P; Fomsgaard A
PLoS One; 2009 Sep; 4(9):e6950. PubMed ID: 19759892
[TBL] [Abstract][Full Text] [Related]
35. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
[TBL] [Abstract][Full Text] [Related]
36. Liposome-based cationic adjuvant formulations (CAF): past, present, and future.
Christensen D; Agger EM; Andreasen LV; Kirby D; Andersen P; Perrie Y
J Liposome Res; 2009; 19(1):2-11. PubMed ID: 19515003
[TBL] [Abstract][Full Text] [Related]
37. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
[TBL] [Abstract][Full Text] [Related]
38. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
[TBL] [Abstract][Full Text] [Related]
39. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
[TBL] [Abstract][Full Text] [Related]
40. A Liposome-Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization.
Christensen D; Bøllehuus Hansen L; Leboux R; Jiskoot W; Christensen JP; Andersen P; Dietrich J
ACS Nano; 2019 Feb; 13(2):1116-1126. PubMed ID: 30609354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]